Study: Gene impedes recovery from Alcoholism

People who are alcohol-dependent and who also carry a particular variant of a gene run an increased risk of premature death. This is a recent finding from the interdisciplinary research at the Department of Psychology and the Sahlgrenska Academy at the University of Gothenburg, Sweden.

Researchers in the longitudinal project Göteborg Alcohol Research Project (GARP) have been investigating the dopamine D2 receptor gene and found that a variant of this gene is overrepresented in people with severe alcohol dependency, and that it is linked to a number of different negative consequences that can be of vital significance to the person affected.

“Our research shows that alcohol-dependent individuals, who are also carriers of this gene variant, run 10 times the risk of dying prematurely, compared with the average population,” says Claudia Fahlke, a representative from the research team.

In a study published recently in the journal Alcohol and Alcoholism (issue 46), the research team shows that this gene variant also appears to be associated with a higher tendency among these individuals to suffer a relapse, even if they have undergone treatment for their alcohol dependency. This may provide one explanation as to the higher mortality rate in people suffering from alcohol dependency, who are carriers of this gene variant.

“This knowledge emphasises the importance of developing methods for early identifying individuals who are also carriers of this gene variant, since the consequences can be so serious,” says Jan Balldin at the Sahlgrenska Academy, University of Gothenburg.

NIH to Support Addiction Medicine Education Programs

Wednesday, October 26, 2011
Contact:NIAAA Press Office 301-443-3860

NIH grant will help translate addiction research into practice

A new grant will help establish a core of post-graduate addiction medicine education programs in academic medical centers throughout the United States. The National Infrastructure for Translating Addiction Research into Clinical Practice grant, awarded last month to the University at Buffalo School of Medicine and Biomedical Sciences, will provide about $900,000 over a two-year period. The grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, and strengthens the foundation for training clinicians in the emerging specialty of addiction medicine.

“We are very excited about this opportunity to help medical students and residents in a variety of specialties who are interested in addiction medicine apply advances in research to real-world practice,” says NIAAA Acting Director Kenneth Warren, Ph.D. “This critical investment in our nation’s health will ultimately improve patient care and reduce the medical, social, and financial burden of the addiction disorders.”

“There is a shortage of academically oriented addiction medicine physicians qualified to conduct clinical research on addictions, to translate this research into practice, and to teach medical students and a wide range of residents about addiction in academic medical centers,” says Co-Principal Investigator Richard D. Blondell, M.D., professor of family medicine at the University at Buffalo, N.Y., and chair of the Residency Training and Accreditation Committee of the American Board of Addiction Medicine (ABAM) Foundation. “This grant will allow established leaders in addiction medicine to help bridge the gap between research and medical education on one hand and clinical practice on the other, and train a new cohort of leaders who will continue to advance the field.”

ABAM Foundation President-Elect Jeffrey Samet, M.D., professor of medicine and community health sciences at Boston University Schools of Medicine and Public Health, is also a co-principal investigator on the grant. In addition to Drs. Blondell and Samet, other key members of the ABAM Foundation will be actively involved in the project.

The goals of the project are to establish a National Addiction Medicine Residency Assistance Council (NAMRAC) that will develop standards of excellence for physician training; identify up to 10 addiction medicine model residency programs; and disseminate curricula and related products and recruit new members to NAMRAC so it can serve as an ongoing resource for development of additional addiction medicine residency programs.

The project is designed to rapidly deploy intensive assistance to the model residencies to help them overcome the barriers that frequently thwart new programs. The model residencies, in turn, will produce educational products, including research-to- practice physician education modules that can be used both in physician training and in helping practicing physicians to incorporate the latest knowledge from alcohol and addictions research into their patient care.

The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health, is the primary U.S. agency for conducting and supporting research on the causes, consequences, prevention, and treatment of alcohol abuse, alcoholism, and alcohol problems. NIAAA also disseminates research findings to general, professional, and academic audiences. Additional alcohol research information and publications are available at www.niaaa.nih.gov.

Misuse of Pain Medication May Be Pathway to High-Risk Drug Behaviors

Philadelphia (July 22, 2011)—A new study by researchers at Drexel University’s School of Public Health suggests that abuse of prescription painkillers may be an important gateway to the use of injected drugs such as heroin, among people with a history of using both types of drugs. The study, published in the International Journal of Drug Policy, explores factors surrounding young injection drug users’ initiation into the misuse of opioid drugs. Common factors identified in this group included a family history of drug misuse and receiving prescriptions for opioid drugs in the past. The results support a need for efforts to prevent misuse of prescription drugs, particularly during adolescence.

“Participants were commonly raised in household where misuse of prescription drugs, illegal drugs, or alcohol, was normalized,” explains Dr. Stephen Lankenau, an associate professor in the School of Public Health and principal investigator of the study.  “Access to prescription medications – either from a participant’s own source, a family member, or a friend – was a key feature of initiation into prescription drug misuse.”

In numerous cases, the desire to experiment with a prescription opioid drug (the common class of drugs that includes codeine and oxycodone), combined with financial incentives or pressures from friends to sell available quantities, resulted in escalated patterns of opioid misuse, according to the study.

Lankenau and colleagues also describe two key findings as evidence of an emerging dynamic among misuse of opioid drugs and the use of injection drugs. First, four of five IDUs misused an opioid before injecting heroin, in contrast to more conventional patterns of using opioids as a substitute drug after initiating heroin use.

Second, in nearly one out of four young IDUs in this study, a prescription opioid was the first type of drug they injected. Prescription opioids are rarely reported at initiation into injection drug use amongst young IDUs. All but two of these participants later transitioned into injecting heroin.

Opioid misuse is an important public health concern due to the increasing association of opioids with drug dependence and fatal overdose, and much research has focused on the factors affecting how and when people initially misuse opioids. However, descriptive data about initiation into prescription opioid misuse among young injection drug users are scarce.

To fill this gap, in this study researchers interviewed 50 young IDUs aged 16 and 25 years old in New York and Los Angeles, who had misused a prescription drug at least three times in the past three months, to study contextual factors leading to their use of opioid drugs. Participants were recruited in natural settings, such as parks, streets, and college campuses, during 2008 and 2009. A mixed-methods research design was utilized that collected both quantitative and qualitative data.

Additional findings and descriptors of the study population include:

  • Most were white, heterosexual males in their early 20s
  • Many did not complete high school, were expelled from school, or held back a grade
  • Nearly all were homeless at some point, most were currently homeless, and most regarded themselves as “travelers,” (i.e., moving from city to city in search of work, housing, or adventure)
  • Most had received a psychological diagnosis, such as depression, anxiety, or Attention Deficit Hyperactivity Disorder (ADHD), and many had a history of drug treatment
  • Most generally regarded prescription opioids as readily accessible, valued commodities that could be traded or sold
  • Nearly three-quarters had been prescribed an opioid in their lifetime, which occurred on average at 14.6 years old, often for common ailments such as dental procedures or sports injuries
  • Most witnessed family members misuse one or more substances during childhood and adolescence, ranging from alcoholism to injecting heroin

The authors conclude that prevention efforts, especially during adolescence, are needed, and that parents and guardians need to carefully monitor and safeguard all prescription medications, particularly opioids, within the household. Although households where drug use is normalized or where broader social or psychological problems exist are more difficult to remedy with prevention efforts or policy changes, future research examining prescription opioid misuse among a range of adolescents and young adults to better understand the contextual and environmental factors of drug use may yield additional solutions.

The article was co-authored by Karol Silva (Drexel University); Michelle Teti (University of Missouri); Alex Harocopos (National Development and Research Institutes); and Jennifer Jackson Bloom and Meghan Treese (Children’s Hospital Los Angeles).

Lankenau is also principal investigator of two studies evaluating the effectives of overdose prevention programs in Los Angeles and Philadelphia.

Lankenau is an associate professor in the Department of Community Health & Prevention at the Drexel University School of Public Health.  He received his PhD and MA degrees in Sociology from the University of Maryland.  He earned his BA in Sociology at the University of Vermont.